Sapu Bioscience has two pharmacological agents in clinical trials to manage Covid-19, the disease caused by the SARS-CoV-2 virus. OT-101 work by inhibiting TGF-β to neutralize the SARS-CoV-2 virus.
Upon assessing the broad impact of the SARS-CoV-2 virus and associated COVID-19 complications, the company tested OT-101 and Artemisinin, both of which showed potent activity in the lab and promising data for treating the virus infection and associated complications based on the their mechanism of action.
